Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 5473

Sort by

Sort Order Select

Journal Articles

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Wendan Xu, Philipp Berning, Georg Lenz

Blood (2021) 138 (13): 1110–1119.

https://doi.org/10.1182/blood.2020006784

Published: 2021

Journal Articles

Hyperstable SGK1 steps out of AKT’s shadow

Franziska Gehringer, Alexey Ushmorov

Blood (2021) 138 (11): 917–918.

https://doi.org/10.1182/blood.2021012518

Published: 2021

Journal Articles

SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence

Jie Gao, Eirini Sidiropoulou, Ieuan Walker, Joanna A. Krupka, Karol Mizielinski, Zelvera Usheva, Shamith A. Samarajiwa, Daniel J. Hodson

Blood (2021) 138 (11): 959–964.

https://doi.org/10.1182/blood.2020010432

Published: 2021

Includes: Supplemental data

Journal Articles

Killing 2 birds with 1 stone in DLBCL

R. Eric Davis

Blood (2021) 138 (10): 822–824.

https://doi.org/10.1182/blood.2021011933

Published: 2021

Journal Articles

Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL

Blood (2021) 138 (10): 871–884.

https://doi.org/10.1182/blood.2020009404

Published: 2021

Includes: Supplemental data

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

Epigenetic balance in DLBCL

Elisa Oricchio

Blood (2021) 138 (5): 355–356.

https://doi.org/10.1182/blood.2021011647

Published: 2021

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado

Blood (2021) 137 (21): 2947–2957.

https://doi.org/10.1182/blood.2020008528

Published: 2021

Includes: Supplemental data

Journal Articles

Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era? Blood . 2021;137(10):1416-1423.

Blood (2021) 137 (20): 2854–2855.

https://doi.org/10.1182/blood.2021011979

Published: 2021

Journal Articles

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Blood (2021) 137 (20): 2785–2799.

https://doi.org/10.1182/blood.2020005244

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

DLBCL outcomes: much ventured, much GAINED

Andrew Davies

Blood (2021) 137 (17): 2277–2278.

https://doi.org/10.1182/blood.2020009964

Published: 2021

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Blood (2021) 137 (16): 2196–2208.

https://doi.org/10.1182/blood.2020007193

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Neeta Bala Tannan, Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A. Heller, Anas Younes

Blood (2021) 137 (15): 2057–2069.

https://doi.org/10.1182/blood.2020008017

Published: 2021

Includes: Supplemental data

Journal Articles

Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood . 2020;135(13):996-1007.

Blood (2021) 137 (15): 2126.

https://doi.org/10.1182/blood.2021011546

Published: 2021

Journal Articles

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms

Blood (2021) 137 (14): 1905–1919.

https://doi.org/10.1182/blood.2020009088

Published: 2021

Includes: Supplemental data

Journal Articles

Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice

Javier Raboso-Gallego, Ana Casado-García, Xiaoyu Jiang, Marta Isidro-Hernández, Andrew J. Gentles, Shuchun Zhao, Yaso Natkunam, Oscar Blanco, Verónica Domínguez, Belén Pintado, Diego Alonso-López, Javier De Las Rivas, Carolina Vicente-Dueñas, Izidore S. Lossos, Isidro Sanchez-Garcia

Blood (2021) 137 (13): 1741–1753.

https://doi.org/10.1182/blood.2020004996

Published: 2021

Includes: Supplemental data

Journal Articles

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.

Blood (2021) 137 (13): 1844.

https://doi.org/10.1182/blood.2021011330

Published: 2021

NARROW

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Hyperstable SGK1 steps out of AKT’s shadow

SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence

Killing 2 birds with 1 stone in DLBCL

Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Epigenetic balance in DLBCL

Characterization of DLBCL with a PMBL gene expression signature

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era? Blood . 2021;137(10):1416-1423.

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

DLBCL outcomes: much ventured, much GAINED

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood . 2020;135(13):996-1007.

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms

Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only